These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28609428)

  • 1. Comparison table: some drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):e104-e106. PubMed ID: 28609428
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison table: Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Dec; 59(1536):e210-e212. PubMed ID: 29232357
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Dec; 59(1536):203-210. PubMed ID: 29232356
    [No Abstract]   [Full Text] [Related]  

  • 4. Abaloparatide (Tymlos) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):97-98. PubMed ID: 28609423
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
    Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison table: some drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2020 Jul; 62(1546):e112-e114. PubMed ID: 32728010
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of glucocorticoid-induced osteoporosis: What is new?
    Compston J
    Int J Rheum Dis; 2019 Sep; 22(9):1595-1597. PubMed ID: 31478605
    [No Abstract]   [Full Text] [Related]  

  • 8. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of osteoporosis: current state of the art.
    Hamrick I; Schrager S; Nye AM
    Wien Med Wochenschr; 2015 Feb; 165(3-4):54-64. PubMed ID: 25502850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACOG Practice Bulletin N. 129. Osteoporosis.
    Committee on Practice Bulletins-Gynecology, The American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2012 Sep; 120(3):718-34. PubMed ID: 22914492
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs for the treatment of metabolic bone diseases.
    Drake MT; Cremers S; Russell RG; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1049-1051. PubMed ID: 30950086
    [No Abstract]   [Full Text] [Related]  

  • 13. Stabilized severe osteoporosis: should the treatment be stopped?
    Paccou J; Confavreux CB; David C; Leboime A; Mehsen N; Cortet B
    Joint Bone Spine; 2010 Dec; 77 Suppl 2():S120-7. PubMed ID: 21211749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and management of denosumab discontinuation.
    Chapurlat R
    Joint Bone Spine; 2018 Oct; 85(5):515-517. PubMed ID: 29317292
    [No Abstract]   [Full Text] [Related]  

  • 15. Denosumab (prolia) for treatment of postmenopausal osteoporosis.
    Johnson GL
    Am Fam Physician; 2012 Feb; 85(4):334-6. PubMed ID: 22335312
    [No Abstract]   [Full Text] [Related]  

  • 16. [Not Available].
    Wildpaner D; Pavese C; Weber M
    Praxis (Bern 1994); 2017 Apr; 106(8):421-427. PubMed ID: 28401777
    [No Abstract]   [Full Text] [Related]  

  • 17. One year in review 2018: progress in osteoporosis treatment.
    Figliomeni A; Signorini V; Mazzantini M
    Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Osteoporosis therapy. Drugs for strong bones].
    MMW Fortschr Med; 2013 Nov; 155(20):26. PubMed ID: 24482919
    [No Abstract]   [Full Text] [Related]  

  • 19. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
    Capozzi A; Lello S; Pontecorvi A
    Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone-Targeted Therapy in Early Breast Cancer.
    Jerzak KJ; Raphael J; Desautels DN; Blanchette PS; Tyono I; Pritchard KI
    Oncology (Williston Park); 2018 Nov; 32(11):562-9. PubMed ID: 30474104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.